Scalper1 News
Big pharma Merck (MRK) upped its ante in the hepatitis C game Monday by agreeing to buy Idenix Pharmaceuticals (IDIX) for $3.85 billion. Idenix’s stock jumped more than 230% on the stock market today , near 24.10, while Merck’s dipped a fraction. Merck agreed to pay $4.50 a share for Idenix, triple its Friday closing price, for its portfolio of three Scalper1 News
Scalper1 News